These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35598602)

  • 1. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
    Stuver R; Shah GL; Korde NS; Roeker LE; Mato AR; Batlevi CL; Chung DJ; Doddi S; Falchi L; Gyurkocza B; Hamilton A; Lin YH; Jakubowski AA; Joffe E; Landau HL; Lin RJ; Mailankody S; Palomba ML; Park JH; Perales MA; Ponce DM; Ramanathan LV; Salles GA; Scordo M; Seo SK; Shah UA; Stein EM; Straus D; Usmani SZ; Young JW; Zelenetz AD; Noy A; Vardhana SA
    Cancer Cell; 2022 Jun; 40(6):590-591. PubMed ID: 35598602
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
    J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
    Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
    Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.
    Lee YJ; Kim HK; Kim Y; Park SH; Lim JH; Jung J; Choi YS; Jo JC
    Ann Hematol; 2024 Jul; 103(7):2533-2539. PubMed ID: 38678486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
    Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL
    Front Immunol; 2023; 14():1259725. PubMed ID: 37928549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
    Focosi D; Casadevall A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
    Levin MJ; Ustianowski A; De Wit S; Launay O; Avila M; Templeton A; Yuan Y; Seegobin S; Ellery A; Levinson DJ; Ambery P; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Near KA; Padilla KW; Psachoulia K; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    N Engl J Med; 2022 Jun; 386(23):2188-2200. PubMed ID: 35443106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.
    Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X
    Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment.
    Vellas C; Kamar N; Izopet J
    J Infect; 2022 Nov; 85(5):e162-e163. PubMed ID: 35878684
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
    Bender Ignacio RA; Wohl DA; Arends R; Pilla Reddy V; Mu Y; Javan AC; Hughes MD; Eron JJ; Currier JS; Smith D; Chew KW; Gibbs M; Fletcher CV
    Clin Pharmacol Ther; 2022 Dec; 112(6):1207-1213. PubMed ID: 35797235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
    Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
    Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
    Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
    J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
    Okada H; Ishikawa K; Itoh Y; Noda Y; Eto T; Pilla Reddy V; Chen CC; Gibbs M; Johnsson E
    J Infect Chemother; 2023 Nov; 29(11):1061-1067. PubMed ID: 37524201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
    Kertes J; Shapiro Ben David S; Engel-Zohar N; Rosen K; Hemo B; Kantor A; Adler L; Shamir Stein N; Mizrahi Reuveni M; Shahar A
    Clin Infect Dis; 2023 Feb; 76(3):e126-e132. PubMed ID: 35904210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
    Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.